• Chemerin–cNTS Signaling Raises Sympathetic Activity

  2026-08-16

  A 2024 European Journal of Neuroscience study identifies a chemerin–CMKLR1–NADPH oxidase–superoxide pathway in the caudal nucleus tractus solitarius that increases renal sympathetic activity, arterial pressure, and heart rate. Pharmacological comparison further indicates that downstream transmission through the paraventricular nucleus depends on NMDA, rather than AMPA/kainate, receptors, clarifying how CNQX should be interpreted in this cardiovascular circuit.

• Alisol A, Cholesterol, and VCI Mechanisms

  2026-08-15

  A 2025 Theranostics study identifies NAMPT-centered AMPK/NAMPT/SIRT1 signaling as a mechanistic link between brain cholesterol imbalance, oxidative stress, defective mitophagy, and atherosclerosis-related vascular cognitive impairment. Using genetic, pharmacological, behavioral, ultrastructural, and lipidomic approaches, the work positions Alisol A as a candidate neuroprotective intervention while highlighting the limitations of translating mouse findings to human disease.

• Pazopanib (GW-786034) in ATRX-Deficient Glioma

  2026-08-14

  Pazopanib (GW-786034) enables a genotype-aware workflow for studying receptor tyrosine kinase dependence, angiogenesis inhibition, and tumor growth suppression. This guide connects ATRX-deficient glioma findings with practical dose-response, signaling, combination, and troubleshooting strategies for reproducible cancer research.

• Dorsomorphin 2HCl: AMPK Inhibitor Workflows

  2026-08-14

  Dorsomorphin 2HCl helps separate AMPK-dependent metabolic effects from probiotic or nutrient interventions in liver models while also enabling BMP pathway and osteogenesis studies. This practical guide covers solvent handling, assay design, pathway-specific readouts, and troubleshooting for more interpretable preclinical experiments.

• Urolithin A: Mitochondrial Quality Control

  2026-08-13

  Urolithin A is a gut microbiota-derived metabolite studied as a mitophagy activator for mitochondrial quality control. Preclinical and human studies support research into mitochondrial function and skeletal muscle mitochondrial gene expression modulation, but they do not establish broad clinical efficacy.

• Pentoxifylline Workflows for Inflammation Research

  2026-08-13

  Pentoxifylline connects cAMP-centered phosphodiesterase inhibition with practical inflammation, infection, psoriasis, and sperm-motility assays. This workflow-focused guide covers concentration selection, endpoint design, cross-domain limitations, and troubleshooting for more reproducible results.

• Lambda Protein Phosphatase for BMAL1 Studies

  2026-08-12

  Use Lambda Protein Phosphatase to separate phosphorylation-dependent effects from protein abundance, antibody binding, and condensate formation. This workflow applies λ-PPase to BMAL1 phase-separation experiments, phospho-specific antibody validation, and functional protein assays with defined Mn²⁺-dependent reaction conditions.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-08-12

  Chen et al. integrated carbapenemase-gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element profiling, and ERIC-PCR to characterize resistant Enterobacter cloacae across eight Guangdong teaching hospitals. The study identifies plasmid-associated blaNDM-1 and efficient horizontal transfer as central surveillance priorities, while also showing that clonally related strains can circulate across departments and institutions.

• Trichostatin A: Designing Better HDAC Assays

  2026-08-11

  Trichostatin A (TSA) is more than a broad HDAC inhibitor: it is a controllable probe for linking histone acetylation to cell-state and metabolic phenotypes. This guide translates cancer and dendritic-cell evidence into better assay-design decisions, with attention to dose, exposure, solvent, and interpretation.

• GW 4869 for Exosome and Ceramide Studies

  2026-08-11

  GW 4869 helps separate neutral sphingomyelinase-dependent vesicle release from downstream recipient-cell signaling. This practical guide applies GW 4869 hydrochloride hydrate to BMSC exosome studies inspired by lithium-enhanced osteogenesis, with dose-planning, controls, and troubleshooting strategies for cleaner mechanistic conclusions.

• Vidarabine monohydrate: Assay Workflows

  2026-08-10

  Build reproducible antiviral assays around Vidarabine monohydrate with DMSO-first formulation, orthogonal viral readouts, and controls that separate DNA replication interference from cytotoxicity. The workflow is tailored to herpes simplex virus research while adapting a screening-and-validation principle from a distinct 2025 molecular pharmacology study.

• Dextrose in Hypoxia and Immunometabolism Research

  2026-08-09

  Dextrose (D-glucose) gives researchers a controllable nutrient variable for modeling glycolysis, tumor hypoxia, immune-cell competition, and cellular energy production. This practical guide translates immunometabolism concepts into reproducible media preparation, oxygen–glucose experiments, assay controls, and troubleshooting decisions.

• Ro 3306: Selective CDK1 Inhibitor Guide

  2026-08-08

  Ro 3306 is an ATP-competitive CDK1 inhibitor that targets CDK1/cyclin B1 and CDK1/cyclin A, producing a controllable G2/M block. Its value extends from cancer cell synchronization to DNA repair mechanism study, but Ki values, cellular responses, and DNA repair phenotypes require separate interpretation.

• A20, Oxidized Self-DNA, and AKI Inflammation

  2026-08-07

  The reference study identifies oxidized self-DNA as a driver of acute kidney injury through coordinated cGAS–STING signaling and NLRP3 inflammasome activation. It further shows that A20 and an A20-derived peptide suppress NEK7-dependent pyroptosis, providing a mechanistic basis for future AKI interventions.

• Cefiderocol Efficacy Against Resistant European Enterobacter

  2026-08-07

  The referenced study systematically evaluated cefiderocol's in vitro activity against a large collection of European Enterobacterales, including strains resistant to meropenem and advanced β-lactam/β-lactamase inhibitor combinations. Its findings highlight cefiderocol as a highly active single-agent option for multidrug-resistant isolates, underscoring the need for early susceptibility testing in clinical microbiology workflows.

16049 records 1/1070 page Next 12345 下5页 Last page